

Short communication

Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography

Estelle Cateau^a, Nicolas Tournier^a, Antoine Dupuis^b,
Gwenaël Le Moal^c, Nicolas Venisse^{a,*}

^a *Service de Pharmacocinétique, CHU Poitiers, BP 577, 86021 Poitiers Cedex, France*

^b *Service Pharmacie, CHU Poitiers, BP 577, 86021 Poitiers Cedex, France*

^c *Service de Maladies Infectieuses et Tropicales, CHU Poitiers, BP 577, 86021 Poitiers Cedex, France*

Received 18 January 2005; received in revised form 21 April 2005; accepted 21 April 2005

Available online 31 May 2005

Abstract

Atazanavir is a new HIV-1 protease inhibitor. A simple high-performance liquid chromatographic method using UV detection was developed and validated for the analysis of atazanavir in human plasma. The sample clean up was carried out using solid-phase extraction with OASIS[®] MCX cartridge. The chromatographic separation was achieved on a Kromasil[®] C₁₈ (150 mm × 3 mm, 5 μm) column with a mobile phase consisting of acetonitrile and water (38:62 v/v) delivered isocratically. The effluent of the column was monitored at a wavelength of 210 nm. The assay was linear over the concentration range of 0.156 to 10 μg/ml and the limit of quantification was 0.156 μg/ml. The method was also validated with respect to recovery, precision, accuracy and specificity.

This method is suitable for therapeutic drug monitoring of atazanavir and can be easily reproduced with standard equipment.
© 2005 Elsevier B.V. All rights reserved.

Keywords: Reversed-phase chromatography; Solid-phase extraction; Protease inhibitors; Atazanavir; Therapeutic drug monitoring

1. Introduction

Atazanavir (ATZ) (Reyataz[®]) is a new azapeptide inhibitor of HIV-1 protease. ATZ possesses unique HIV resistance profile and favourable pharmacokinetic properties allowing once-daily dosing. Unlike other protease inhibitors (PIs), ATZ does not negatively impact the lipid profile.

Reyataz[®] was approved for treatment of HIV by the European Medicines Agency (EMA) in 2004 and indicated in combination with other anti-HIV drugs. ATZ use is recommended boosted, with low dose ritonavir (rtv), which acts as a pharmacokinetic enhancer.

PIs are appropriate candidates for therapeutic drug monitoring (TDM) [1]; these compounds exhibit significant inter-individual pharmacokinetic variability and relationships between plasma concentrations and antiviral effect. In

particular, sub-optimal concentrations of PIs limit drug efficacy. TDM is also of clinical relevance to prevent the appearance of toxic side effects.

As ATZ undergoes cytochrome P450 3A4 (CYP 3A4) metabolism, numerous drug–drug interactions are expected and TDM provides a useful tool to detect and manage them. Particularly, interactions may be very unpredictable using the new therapeutic option with double-boosted PIs [2], thus requiring TDM.

TDM also permits to document medication compliance as non-adherence to treatment affects the success of antiretroviral therapy and is related to virologic failure. As recommended by French guidelines for HIV treatment [3], TDM has been introduced in our centre as a part of multidisciplinary approach including physician, virologist and pharmacist [4]. This approach aims to optimize clinical use of antiretroviral drugs.

Only few analytical methods have been described for the determination of ATZ in biological samples. Most of

* Corresponding author. Tel.: +33 549 454984; fax: +33 549 454955.
E-mail address: n.venisse@chu-poitiers.fr (N. Venisse).

them used liquid chromatography–tandem mass spectrometry (LC–MS–MS) [5–7]. LC–MS–MS systems are not available in all TDM routine laboratories and other analytical method need to be developed. Colombo et al. [8] have proposed a HPLC method using UV-diode array detection for the simultaneous analysis of PIs, including ATZ, and non-nucleoside reverse transcriptase inhibitors. However, this latter involves a 40 min gradient elution run, requiring equilibration step. Likewise, Dailly et al. [9] have recently proposed a method involving gradient elution and requiring multi-step, time-consuming liquid–liquid extraction.

In this paper, we report the development and validation of a simple solid-phase extraction followed by isocratic high-performance liquid chromatography (HPLC) assay with ultraviolet detection which allows rapid, precise, specific and sensitive quantification of ATZ in plasma.

2. Experimental

2.1. Reagents and solutions

Bristol-Myers Squibb (New Brunswick, NJ, USA) kindly supplied ATZ sulfate. The internal standard (IS), prazepam, was purchased from Sigma Chemical Company (Saint Quentin Fallavier, France). HPLC grade acetonitrile, methanol and 1 M HCl were purchased from Carlo Erba (Rueil Malmaison, France). Pure water was obtained from a Millipore Milli-Q plus water purification system (Saint Quentin en Yvelines, France). Acetic acid and ammonia solution were purchased from Merck (Strasbourg, France).

Drug free human plasma was purchased from centre atlantique blood transfusion centre (Nantes, France).

Solid-phase extraction cartridges (Oasis[®] MCX 1cc) were obtained from Waters (Saint Quentin en Yvelines, France).

Stock solutions of ATZ (400 µg/ml) and of IS (100 µg/ml) were both prepared in volumetric flasks by dissolving an accurately weighted amounts of ATZ sulfate or IS in methanol. All stock solutions were stored at +4 °C for 6 months.

ATZ working solutions were prepared from a 1/4 dilution of the stock solution in methanol.

The calibration plasma standards (0.156, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml) were prepared using 1 ml of drug-free human plasma samples spiked with 100 µl standard solutions of ATZ (1.5625–100 µg/ml), obtained by appropriate dilution in methanol of the stock solution.

Plasma quality controls (QC) were also prepared using the same procedure in order to evaluate the precision, accuracy, recovery, quantification and detection limits of the method. These concentrations were based on human plasma levels usually determined in pharmacokinetic studies.

QC samples were prepared at three levels and stored at –20 °C until analysis:

- low level corresponding to the limit of quantification (LOQ): 0.156 µg/ml;

- middle level: 2 µg/ml;
- high level: 7 µg/ml.

2.2. HPLC system

The analytical column (Kromasil[®] C₁₈, 5 µm, 150 mm × 3 mm) and the ChromSep[®] C₁₈ guard column (10 mm × 2 mm) were obtained from Varian (Les Ulis, France).

The HPLC system consisted of a L-6000 Merck pump (VWR, Fontenay-sous-Bois, France), a Waters 717 plus Autosampler injector (Saint Quentin en Yvelines, France), a Waters 2487 UV detector (Saint Quentin en Yvelines, France) and a PC with Kromasystem 2000 integrator from Bio-Tek instruments (Trappes, France).

The mobile phase consisted of a mixture of acetonitrile and water (38:62 v/v) and was filtered through a 0.2 µm nylon filter membrane (Lida Manufacturing Corp., USA) before use. The HPLC system was operated isocratically at a flow rate of 1.0 ml min⁻¹ and the effluent of the column was monitored at a wavelength of 210 nm.

2.3. Plasma sample pre-treatment

Patient's blood samples were collected in tubes with anti-coagulant (lithium heparinate) and centrifuged (3000 × g for 10 min at 20 °C). Plasma samples were then stored at –20 °C prior to analysis. They were handled according to the standard procedure for bio-hazardous samples.

3. Extraction technique

Fifty µl of IS stock solution and 100 µl of 5N acetic acid were added to calibration standard, quality control and patient plasma samples. After mixing on a Vortex[®] mixer for 30 s, plasma was transferred onto the solid-phase extraction cartridge conditioned with 1 ml methanol and 1 ml purified water. Then cartridge was washed with 1 ml NH₄OH–CH₃OH–H₂O (5:5:90 v/v/v) solution. Elution was finally carried out twice with 500 µl NH₄OH–CH₃OH (5:95 v/v) and the eluate was evaporated to dryness under a gentle stream of nitrogen. The residue was reconstituted in 100 µl of mobile phase and 50 µl were injected in the HPLC system.

3.1. Calibration and calculation procedures

Standard curves were constructed by plotting the peak height ratios of ATZ and IS versus ATZ concentrations. Then a linear regression was performed to calculate the ATZ concentrations of plasma samples from the peak height ratios.

3.2. Assay validation

Assay validation involves linearity, specificity, accuracy, precision, limit of detection (LOD) and limit of

quantification (LOQ) determination. The acceptance criteria used to validate the assay have been published [10].

4. Results and discussion

4.1. Chromatograms and analytical conditions

Fig. 1 shows chromatograms obtained with extracts of (a) drug-free plasma supplemented with IS, (b) plasma spiked with ATZ at a concentration corresponding to the LOQ (0.156 $\mu\text{g/ml}$) and with IS, (c) plasma spiked with ATZ 10 $\mu\text{g/ml}$ and with IS and (d) plasma spiked with IS from a patient orally treated with 300 mg/100 mg ATZ/rtv once a day. The patient's blood sample was collected at the time of minimum plasma concentration C_{through} , i.e. just before the next administration. The ATZ concentration determined in the patient's sample was 0.50 $\mu\text{g/ml}$, and was within the therapeutic range reported for ATZ C_{through} by the French HIV experts group [0.2–1 $\mu\text{g/ml}$] [3].

The mobile phase that gave optimal separation from other antiretroviral drugs was a simple mixture of acetonitrile and purified water (38:62 v/v). Using these chromatographic conditions, retention times of ATZ and IS were 18.5 and 22.0 min, respectively. A higher percentage of acetonitrile led to chromatographic interference with co-administered drugs. Isochratic delivery of the mobile phase was preferred in order to avoid drawbacks of gradient use: equilibration time, solvent consuming, baseline increase, etc.

SPE was selected because it provided a fast and efficient sample preparation and a time- and solvent-sparing technique in comparison with liquid–liquid extraction. We used a mixed-mode polymeric sorbent with reversed-phase and cation-exchange functionalities. The cation-exchange groups provide high selectivity for basic drugs allowing optimal sample cleaning.

Whereas the IS was not chemically related to the analyte, it possessed similar extraction (Table 3) and chromatographic properties. In addition this compound is a pro-drug, which will never be retrieved from human plasma.

4.2. Linearity

The calibration curves in plasma were linear over the range 0.156–10 $\mu\text{g/ml}$ and characterized by the equation: $y = 0.9073x - 0.0852$ ($r^2 = 0.999$, $n = 5$).




Fig. 1. (a) Drug-free plasma, (b) plasma calibration standard (0.156 $\mu\text{g/ml}$, limit of quantification), (c) plasma calibration standard (10 $\mu\text{g/ml}$) and (d) plasma from a patient orally treated with atazanavir. Peaks: 1 = atazanavir (ATZ), 2 = internal standard (EI).

4.3. Limit of detection and limit of quantification

The LOD in human plasma, defined as the concentration giving a signal-to-noise ratio of 3, was 0.078 $\mu\text{g/ml}$.

The LOQ was chosen as the concentration corresponding to the lowest standard of the calibration curve (0.156 $\mu\text{g/ml}$) giving good accuracy ($\geq 88.5\%$, $n = 6$) and precision ($\text{CV} \leq 11\%$, $n = 6$) (Table 1). LOQ is below the lower

Table 1
Within-day precision and accuracy of HPLC method

Concentration added ($\mu\text{g/ml}$)	Concentration found ($\mu\text{g/ml}$) (mean \pm S.D.)	Precision, CV (%)	Accuracy (%)
Within-day ($n = 6$)			
0.156	0.14 \pm 0.003	2	88.5
2	2.02 \pm 0.15	8	101.0
7	6.71 \pm 0.45	6.8	95.9

Table 2

Day-to-day precision and accuracy of the HPLC method

Concentration added ($\mu\text{g/ml}$)	Concentration found ($\mu\text{g/ml}$) (mean \pm S.D.)	Precision CV (%)	Accuracy (%)
Day-to-day ($n = 6$)			
0.156	0.150 \pm 0.017	11	96.2
2	2.01 \pm 0.15	7	100.4
7	7.02 \pm 0.52	7	100.2

Table 3

Absolute recovery of atazanavir (ATZ) and internal standard (IS) from plasma samples following extraction on SPE cartridges

Initial concentrations ($\mu\text{g/ml}$)	Recovery percentage ($n = 3$)
ATZ	
0.156	105
2	95
7	80
IS	
5	80

limit of the therapeutic range reported by the French HIV experts group [3] and provides sufficient sensitivity for routine analysis of human plasma samples.

4.4. Accuracy and precision

The within-day variability of the method was characterized by $\text{CV} \leq 8\%$ (Table 1).

The day-to-day variability in plasma was assessed over 6 days with human plasma samples containing 0.156, 2 and 7 $\mu\text{g/ml}$ of ATZ. The CV for day-to-day analysis was $\leq 11\%$ and the accuracy within 96.2 and 100.4% (Table 2).

4.5. Recovery

The absolute recovery of the SPE was determined by comparing the peak height of ATZ and of IS obtained by analysis of spiked plasma extracts with those obtained by analysis of methanolic standards at the same concentration (Table 3).

4.6. Specificity

The interference from potentially co-administrated drugs was investigated by determining their retention times at the concentration of 10 $\mu\text{g/ml}$. The results are presented in Table 4 and demonstrate the good specificity of the assay since no interference was detected between the drugs tested and ATZ or IS. Furthermore, absence of chromatographic interference was confirmed during routine analysis of plasma samples from patient treated with Reyataz[®]. Neither for specificity nor sensitivity purpose, MS detection appeared indispensable for routine TDM analysis of ATZ.

4.7. Stability

Stability of plasma samples during HIV inactivation (60 °C for 60 min), at room temperature, at -20 °C and

Table 4

Specificity

Molecules	RT
Abacavir	ND
Amphotericin B	ND
Amprenavir	7.7
Atazanavir	18.5
Bromazepam	ND
Diazepam	8.35
Didanosine	ND
Efavirenz	ND
Ethambutol	ND
Fluconazole	ND
Flucytosine	ND
Fluoxetine	15.7
Fluvoxamine	9.8
Indinavir	5.2
Isoniazid	ND
Itraconazole	27.5
Lamivudine	ND
Lopinavir	26.9
Methadone	ND
Nelfinavir M8	27.2
Nelfinavir	ND
Nevirapine	1.3
Nordazepam	5.1
Oxazepam	7.7
Prazepam	22.0
Pyrazinamide	ND
Rifampin	ND
Ritonavir	ND
Saquinavir	ND
Sulfamethoxazole	ND
Vancomycin	ND
Zidovudine	ND

RT: retention time (min) of drugs with the HPLC system; ND: no detectable chromatographic signal with the HPLC system.

after freeze-thaw cycles have been reported elsewhere [8].

5. Conclusion

A rapid, precise, specific and sensitive method for the determination of ATZ in human plasma samples has been developed and validated. This method is suitable for TDM and can be easily reproduced with standard equipment.

References

- [1] J.G. Gerber, E.P. Acosta, J. Clin. Virol. 27 (2003) 117–128.

- [2] A.M. Taburet, G. Raguin, C. Le Tiec, C. Droz, A. Barrail, I. Vincent, L. Morand-Joubert, G. Chene, F. Clavel, P.M. Girard, *Clin. Pharmacol. Ther.* 75 (2004) 310–323.
- [3] J.F. Delfraissy, *Le groupe des Experts, Prise en charge thérapeutique des personnes infectées par le VIH*, Médecine-Sciences Flammarion, Paris, 2004.
- [4] J. Faux, N. Venisse, G. Le Moal, A. Dupuis, S. Bouquet, *Chromatographia* 58 (2003) 421–426.
- [5] K.M. Crommentuyn, H. Rosing, M.J. Hillebrand, A.D. Huitema, J.H. Beijnen, *J. Chromatogr. B* 804 (2004) 359–367.
- [6] M. Jemal, S. Rao, M. Gatz, D. Whigan, *J. Chromatogr. B* 795 (2003) 273–289.
- [7] A. Schuster, S. Burzawa, M. Jemal, E. Loizillon, P. Couerbe, D. Whigan, *J. Chromatogr. B* 788 (2003) 377–386.
- [8] S. Colombo, N. Guignard, C. Marzolini, A. Telenti, J. Biollaz, L.A. Decosterd, *J. Chromatogr. B* 810 (2004) 25–34.
- [9] E. Dailly, F. Raffi, P. Jolliet, *J. Chromatogr. B* 813 (2004) 353–358.
- [10] F. Bressolle, M. Bromet-Petit, M. Audran, *J. Chromatogr. B* 686 (1996) 3–10.